Improvement of HbA1c in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis Treated with bDMARDs

Figures & data

Table 1 Demographic Data of the Whole Population

	Whole Population (N=67)
Males n (%)	28 (41.7%)
Age, years (±SD)	57.8±4.5
RA duration, years	2.8±1.8
Weight, kg (±SD)	84±8.5
Height, m (±SD)	1.69±0.02
BMI, Kg/m2 (±SD)	28.1±3.6

Table 2 Data on DAS28CRP, HbA1c and BMI for Each bDMARD Used, During All Observation Periods

	bDMARD
	Adalimumab		Etanercept		Golimumab		Sarilumab		Tocilizumab
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
DAS28CRP T-3	5.15	0.48	5.16	0.34	5.22	0.36	4.98	0.42	5.18	0.34
DAS28CRP T0	5.08	0.52	5.33	0.34	5.32	0.42	5.26	0.41	5.20	0.23
DAS28CRP T+3	4.11	0.81	3.78	1.03	3.82	0.97	2.94	0.90	2.92	0.63
DAS28CRP T+6	3.61	0.76	3.58	0.81	3.58	0.86	2.83	0.35	2.79	0.64
HbA1c T-3	45.1	6.6	48.1	6.9	45.5	4.9	51.2	6.2	44.6	7.8
HbA1c T0	46	8	51	8	48	7	53	7	47	8
HbA1c T+3	43	6	45	4	44	4	45	2	42	3
HbA1c T+6	42	4	44	3	43	4	45	3	42	3
BMI T-3	27.69	1.21	27.82	1.43	27.85	1.29	28.55	1.42	28.14	0.86
BMI T0	29.33	1.33	28.30	1.35	28.52	1.33	29.39	1.29	28.70	1.17
BMI T+3	28.44	1.45	27.52	1.29	27.89	1.44	28.01	1.45	28.57	1.27
BMI T+6	28.00	0.99	28.26	1.05	28.68	1.11	27.99	0.85	28.92	1.03

Figure 1 DAS28-CRP values during the study from 3 months before to 6 months after the start of therapy with bDMARDs.

Figure 2 HbA1c values during the study from 3 months before to 6 months after the start of therapy with bDMARDs.